Literature DB >> 8971119

Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides.

C P O'Leary1, J Veitch, W F Durward, A M Thomas, J H Rees, H J Willison.   

Abstract

Three patients with acute oropharyngeal palsy had high titre anti-GQ1b and anti-GT1a IgG antibodies. No patients had ophthalmoplegia or ptosis. In all patients limb ataxia or areflexia were present without notable limb weakness. These patients describe an oropharyngeal variant of Guillain-Barré syndrome in terms of anti-GQ1b antibody reactivity and show that high titre anti-GQ1b antibodies, serologically indistinguishable from those found in Miller Fisher syndrome, can occur in a clinical setting without ophthalmoplegia. The anti-GQ1b and anti-GT1a antibody assays may be helpful tests when considering the differential diagnosis of acute oropharyngeal palsy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8971119      PMCID: PMC486666          DOI: 10.1136/jnnp.61.6.649

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  10 in total

1.  An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia).

Authors:  M FISHER
Journal:  N Engl J Med       Date:  1956-07-12       Impact factor: 91.245

2.  Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome.

Authors:  A Chiba; S Kusunoki; T Shimizu; I Kanazawa
Journal:  Ann Neurol       Date:  1992-06       Impact factor: 10.422

3.  Guillain-Barré syndrome with ophthalmoplegia: clinicopathologic study of the central and peripheral nervous systems, including the oculomotor nerves.

Authors:  I Dehaene; J J Martin; K Geens; P Cras
Journal:  Neurology       Date:  1986-06       Impact factor: 9.910

4.  Frequent presence of anti-GQ1b antibody in Fisher's syndrome.

Authors:  N Yuki; S Sato; S Tsuji; T Ohsawa; T Miyatake
Journal:  Neurology       Date:  1993-02       Impact factor: 9.910

Review 5.  Miller Fisher syndrome and other acute variants of Guillain-Barré syndrome.

Authors:  A H Ropper
Journal:  Baillieres Clin Neurol       Date:  1994-04

6.  Two species of antiganglioside antibodies in a patient with a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome.

Authors:  K Mizoguchi; A Hase; T Obi; H Matsuoka; M Takatsu; Y Nishimura; F Irie; Y Seyama; Y Hirabayashi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

7.  Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller Fisher syndrome.

Authors:  H J Willison; J Veitch
Journal:  J Neuroimmunol       Date:  1994-03       Impact factor: 3.478

8.  Acute ataxic neuropathy with cross-reactive antibodies to GD1b and GD3 gangliosides.

Authors:  H J Willison; A Almemar; J Veitch; D Thrush
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

9.  Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside.

Authors:  H J Willison; J Veitch; G Paterson; P G Kennedy
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-02       Impact factor: 10.154

10.  Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies.

Authors:  A Chiba; S Kusunoki; H Obata; R Machinami; I Kanazawa
Journal:  Neurology       Date:  1993-10       Impact factor: 9.910

  10 in total
  17 in total

1.  Distinct immunoglobulin class and immunoglobulin G subclass patterns against ganglioside GQ1b in Miller Fisher syndrome following different types of infection.

Authors:  B Schwerer; A Neisser; H Bernheimer
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Fisher syndrome.

Authors:  Masahiro Mori; Satoshi Kuwabara
Journal:  Curr Treat Options Neurol       Date:  2011-02       Impact factor: 3.598

3.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

Review 4.  Clinical utility of autoantibodies in Guillain-Barre syndrome and its variants.

Authors:  J W Terryberry; Y Shoenfeld; J B Peter
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 5.  Guillain-Barré syndrome: a century of progress.

Authors:  John A Goodfellow; Hugh J Willison
Journal:  Nat Rev Neurol       Date:  2016-11-18       Impact factor: 42.937

6.  Bulbar paralysis associated with Miller-Fisher syndrome and its overlaps in Chinese patients.

Authors:  Qiaoxia Hu; Hongfu Li; Jun Tian; Baorong Zhang
Journal:  Neurol Sci       Date:  2017-11-09       Impact factor: 3.307

7.  Monoclonal antibodies raised against Guillain-Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations.

Authors:  C S Goodyear; G M O'Hanlon; J J Plomp; E R Wagner; I Morrison; J Veitch; L Cochrane; R W Bullens; P C Molenaar; J Conner; H J Willison
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

8.  Ganglioside agglutination immunoassay for rapid detection of autoantibodies in immune-mediated neuropathy.

Authors:  A Alaedini; I Wirguin; N Latov
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

Review 9.  Complex gangliosides as autoantibody targets at the neuromuscular junction in Miller Fisher syndrome: a current perspective.

Authors:  Graham M O'Hanlon; Roland W M Bullens; Jaap J Plomp; Hugh J Willison
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

Review 10.  [Guillain-Barré syndrome after exposure to influenza].

Authors:  H-P Hartung; B Keller-Stanislawski; R A Hughes; H C Lehmann
Journal:  Nervenarzt       Date:  2012-06       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.